CRISPR Therapeutics AG (NASDAQ:CRSP) traded at $119.22 at close of the session on Monday, July 26, made a downward move of -2.49% on its previous day’s price.

Looking at the stock we see that its previous close was $122.27 and the beta (5Y monthly) reads 2.25 with the day’s price range being $118.51 – $123.6099. In terms of its 52-week price range, CRSP has a high of $220.20 and a low of $76.71. The company’s stock has lost about -13.53% over that past 30 days.




3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


CRISPR Therapeutics AG has a market cap of $9.22 billion and is expected to release its quarterly earnings report on Oct 26, 2021 – Nov 01, 2021. Estimates by analysts give the company expected earnings per share (EPS) of $3.52, with the EPS growth for the year raised at -$0.51 for 2021 and -$6.32 for next year. These figures represent 90.40% and -1,139.20% growth in EPS for the two years respectively.

The median projection represents growth squeezing down to 2,223.00% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $465.43 million, or 64,633.00% up from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the CRSP stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 100% Sell.

Based on estimates by 21 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 6 have rated the CRISPR Therapeutics AG (CRSP) stock as a Hold, while 14 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 1 suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is -14.35% off its SMA20 and -6.35% from its 50-day simple moving average. The RSI (14) is pointing at 36.07 while the volatility over the past week is 4.60% and jumps to 5.77% over the past one month. The beta value is 2.26, while the average true range (ATR) is currently pointing at 7.05. The average price target for the stock over the next 12 months is $163.11, with the estimates having a low of $117.00 and a high of $220.00. These price ends are 1.86% and -84.53% off the current price level respectively, although investors could be excited at the prospect of a -38.4% if the CRSP share price touches on the median price of $165.00.

Let’s briefly compare CRISPR Therapeutics AG (CRSP) stock to its peers. We find that current price change of -2.49% and 31.95% over the past 12 months for CRSP competes that of Pieris Pharmaceuticals Inc. (PIRS), which has seen its stock price fall -0.30% in the last trading session and was 15.07% over the last one year. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at 0.24% and 0.24%, respectively, at close of the trading.

Coming back to CRISPR Therapeutics AG (NASDAQ:CRSP), we note that the average 3-month trading volume was 1.38 million, while that of the preceding 10-day period stands at 1.11 million. Current shares outstanding are 75.00 million.

>> 7 Top Picks for the Post-Pandemic Economy

The insiders hold 1.10% of the company’s shares while institutions hold 64.20%. The data shows that short shares as of Jun 14, 2021, stood at 3.36 million at a short ratio of 3.34. This represents a 4.18% short interest in shares outstanding on Jun 14, 2021. Shares short fall in June from the previous month at 3.87 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -22.13% down in year-to-date price movement.



Source link